NWSA
62
2
TGT
25
-24
FDX
36
-4
TRV
53
-3
CMCSA
48
2
AES
39
-4
JNPR
46
3
INTU
51
2
ADP
64
2
MPC
47
3
ZBH
60
-2
KR
34
-3
MAS
51
4
CSX
51
-2
ED
48
3
TEL
60
2
HD
47
-5
AFL
46
-3
AMAT
36
5
EXC
54
-2
NWSA
62
2
TGT
25
-24
FDX
36
-4
TRV
53
-3
CMCSA
48
2
AES
39
-4
JNPR
46
3
INTU
51
2
ADP
64
2
MPC
47
3
ZBH
60
-2
KR
34
-3
MAS
51
4
CSX
51
-2
ED
48
3
TEL
60
2
HD
47
-5
AFL
46
-3
AMAT
36
5
EXC
54
-2
Financhill
Back

InMed Pharmaceuticals 10K Form

Sell
32

INM
InMed Pharmaceuticals

Last Price:
4.56
Seasonality Move:
17.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive INM News And Ratings

See the #1 stock for the next 7 days that we like better than INM

INM Financial Statistics

Sales & Book Value

Annual Sales: $4.6M
Cash Flow: $-1.83M
Price / Cash Flow: 0
Annual Sales: $12.59
Price / Book: 0.36

Profitability

EPS (TTM): -65.40000
Net Income (TTM): $-6.82M
Gross Margin: $1.1M
Return on Equity: -66.76%
Return on Assets: -55.13%

InMed Pharmaceuticals Earnings Forecast

Key InMed Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 24 years for INM is 23.94%.
  • The Selling, General & Administrative Expenses for INM have been equal to 114.20% of Gross Profit Margin.
  • The Research & Development expenses have been 81.89% of Revenue.
  • The Interest Expense is -3.53% of Operating Income.
  • Per Share Earnings over the last 24 years have been positive in 15 years.

InMed Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: INM
Website: inmedpharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.07
Quick Ratio: 4.09

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

INM Technical Analysis vs Fundamental Analysis

Sell
32
InMed Pharmaceuticals (INM) is a Sell

Is InMed Pharmaceuticals a Buy or a Sell?